State Street
VRCA icon

State Street’s Verrica Pharmaceuticals VRCA Stock Holding History

State Street’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$153K Buy
28,916
+5,435
+23% +$34.8K ﹤0.01% 3952
2025
Q4 		$195K Buy
23,481
+2,900
+14% +$16.1K ﹤0.01% 3906
2025
Q3 		$88.7K Buy
20,581
+11,399
+124% +$68.7K ﹤0.01% 4071
2025
Q2 		$48.7K Sell
9,182
-47,523
-84% -$256K ﹤0.01% 4103
2025
Q1 		$251K Buy
56,705
+4,393
+8% +$28.4K ﹤0.01% 3772
2024
Q4 		$366K Buy
52,312
+1,030
+2% +$11.3K ﹤0.01% 3706
2024
Q3 		$744K Buy
51,282
+6,104
+14% +$275K ﹤0.01% 3528
2024
Q2 		$3.29M Buy
45,178
+3,918
+9% +$301K ﹤0.01% 3100
2024
Q1 		$2.44M Buy
41,260
+2,333
+6% +$129K ﹤0.01% 3215
2023
Q4 		$2.85M Buy
38,927
+653
+2% +$26.8K ﹤0.01% 3187
2023
Q3 		$1.49M Buy
38,274
+663
+2% +$33.7K ﹤0.01% 3430
2023
Q2 		$2.17M Buy
37,611
+30,839
+455% +$1.87M ﹤0.01% 3377
2023
Q1 		$440K Buy
6,772
+490
+8% +$29.6K ﹤0.01% 3782
2022
Q4 		$173K Hold
6,282
– – ﹤0.01% 4163
2022
Q3 		$183K Sell
6,282
-2,000
-24% -$68.5K ﹤0.01% 4190
2022
Q2 		$159K Sell
8,282
-14,822
-64% -$745K ﹤0.01% 4309
2022
Q1 		$1.87M Buy
23,104
+462
+2% +$38.1K ﹤0.01% 3592
2021
Q4 		$2.07M Sell
22,642
-123
-0.5% -$13.9K ﹤0.01% 3625
2021
Q3 		$2.85M Buy
22,765
+1,330
+6% +$149K ﹤0.01% 3512
2021
Q2 		$2.42M Sell
21,435
-400
-2% -$48.5K ﹤0.01% 3513
2021
Q1 		$3.31M Sell
21,835
-483
-2% -$66.8K ﹤0.01% 3228
2020
Q4 		$2.57M Sell
22,318
-940
-4% -$86.4K ﹤0.01% 3265
2020
Q3 		$1.8M Sell
23,258
-392
-2% -$32.1K ﹤0.01% 3240
2020
Q2 		$2.6M Buy
23,650
+170
+0.7% +$19.7K ﹤0.01% 3072
2020
Q1 		$2.57M Buy
23,480
+1,028
+5% +$135K ﹤0.01% 2947
2019
Q4 		$3.57M Buy
22,452
+1,609
+8% +$237K ﹤0.01% 3011
2019
Q3 		$3.08M Buy
20,843
+2,710
+15% +$302K ﹤0.01% 3045
2019
Q2 		$2.11M Buy
18,133
+9,645
+114% +$905K ﹤0.01% 3225
2019
Q1 		$918K Buy
8,488
+244
+3% +$28.1K ﹤0.01% 3353
2018
Q4 		$672K Buy
8,244
+3,284
+66% +$399K ﹤0.01% 3401
2018
Q3 		$808K Buy
+4,960
New +$847K ﹤0.01% 3431

Other funds holding VRCA

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street's VRCA Position: Q1 2026 in Review

State Street increased its Verrica Pharmaceuticals (VRCA) stake by 23% in Q1 2026, buying an estimated $34.8K and bringing the position to 28,916 shares worth $153K. The position accounts for ﹤0.01% of the portfolio, ranked #3952.

State Street first reported a position in VRCA in Q3 2018 and has held it in 31 quarters since. The position peaked at $3.57M in Q4 2019. 39 funds tracked by Wall St. Rank hold VRCA as of Q1 2026.

  • State Street held 28,916 shares of Verrica Pharmaceuticals worth $153K as of Q1 2026.
  • State Street bought 5,435 Verrica Pharmaceuticals shares in Q1 2026, an estimated $34.8K.
  • Verrica Pharmaceuticals made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3952 holding.
  • State Street first reported a position in Verrica Pharmaceuticals in Q3 2018 and has held it in 31 quarters since.
  • State Street's Verrica Pharmaceuticals position peaked at $3.57M in Q4 2019.
  • 39 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.